FP7H2020HORIZON
Medizinische Universitat Innsbruck
- Country
- ATAustria
- Defence projects
- 0
- Projects, all programmes
- 83
- As coordinator
- 16
- EU contribution (CORDIS)
- EUR 43,208,324
- Active
- 2007 to 2025
Projects
83 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| EU-ToxRiskAn Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century | H2020 | 2016 | Participant | Not stated |
| EHVAEuropean HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates | H2020 | 2016 | Participant | EUR 515,000 |
| IMMUTRAINTraining Network for the Immunotherapy of Cancer | H2020 | 2015 | Participant | EUR 255,934 |
| OPATHYFrom Omics to Patient: Improving Diagnostics of Pathogenic Yeasts | H2020 | 2015 | Participant | EUR 255,934 |
| MDS-RIGHTProviding the right care to the right patient with MyeloDysplastic Syndrome at the right time | H2020 | 2015 | Participant | EUR 154,926 |
| APERIMAPERIM: Advanced bioinformatics platform for PERsonalised cancer IMmunotherapy | H2020 | 2015 | Coordinator | EUR 420,540 |
| FAIR-PARK-IIConservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone | H2020 | 2015 | Participant | EUR 226,735 |
| DISCHARGEDiagnostic Imaging Strategies for Patients with Stable Chest Pain and Intermediate Risk of Coronary Artery Disease: Comparative Effectiveness Research of Existing Technologies | FP7 | 2014 | Participant | EUR 154,304 |
| SYMPATHReach α-synuclein-dependent neurodegeneration: clinical development of therapeutic AFFITOPE vaccines for Parkinson’s disease and multisystem atrophy | FP7 | 2013 | Participant | EUR 366,012 |
| GANNET53A drug strategy targeting heat shock protein 90 to combat metastatic, p53 mutant ovarian cancer. | FP7 | 2013 | Coordinator | EUR 1,564,140 |
| NCRNAPAINNon-coding RNAs in neurogenic and neuropathic pain mechanisms and their application for risk assessment, patient stratification and personalised pain medicine | FP7 | 2013 | Coordinator | EUR 1,699,160 |
| MultISynMultimodal Imaging of rare Synucleinopathies | FP7 | 2013 | Participant | EUR 537,410 |
| MITIGATEClosed-loop Molecular Environment for Minimally Invasive Treatment of Patients with metastatic Gastrointestinal Stromal Tumours | FP7 | 2013 | Participant | EUR 331,400 |
| InfantBilingualBrainLanguage learning in monolingual and bilingual infants: Evidence from electrophysiological and optical signals | FP7 | 2013 | Coordinator | EUR 180,191 |
| SAXCESSStructure-function analysis of the human plasma glycoprotein afamin, a potential drug target in the treatment of metabolic syndrome. | FP7 | 2013 | Coordinator | EUR 249,890 |
| HBPThe Human Brain Project | FP7 | 2013 | Participant | EUR 624,966 |
| EUROFORGEN-NOEEUROPEAN FORENSIC GENETICS Network of Excellence | FP7 | 2012 | Participant | EUR 454,292 |
| ABIRISKAnti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk | FP7 | 2012 | Participant | EUR 714,470 |
| EUROHYP-1European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke | FP7 | 2012 | Participant | EUR 2,559 |
| ECRIN-IAEuropean Clinical Research Infrastructures Network - Integrating Activity | FP7 | 2012 | Participant | EUR 57,400 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.